 Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its DELigase platform Clinical data updates planned for Nurixs two first-in-class BTK degraders in 2023 Clinical data update planned for Nurixs first-in-class CBL-B inhibitor in 2023 Significant progress made across deep pipeline of preclinical candidates SAN ... The post Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 20... 